Loading...
Loading...
Browse all stories on DeepNewz
VisitICMR and Panacea Biotec Start Phase 3 Trial for DengiAll, India's First Indigenous Dengue Vaccine
Aug 14, 2024, 12:15 PM
The Indian Council of Medical Research (ICMR) and pharmaceutical company Panacea Biotec have initiated the first-ever Phase 3 clinical trial for a dengue vaccine in India. The indigenous vaccine, named DengiAll, marks a significant advancement in the fight against dengue. The trial began with the administration of the first dose in Rohtak, Haryana, ahead of India's Independence Day 2024. This development comes as dengue cases remain a concern in India, with 289,235 cases and 485 deaths reported in 2023, according to the National Centre for Vector Borne Diseases Control Programme.
View original story
Markets
No • 50%
Yes • 50%
National Centre for Vector Borne Diseases Control Programme annual report
No • 50%
Yes • 50%
Official announcement from the Indian Council of Medical Research (ICMR) or the Central Drugs Standard Control Organization (CDSCO)
No • 50%
Yes • 50%
Official announcement from ICMR or Panacea Biotec
Less than 5,000 • 25%
More than 20,000 • 25%
10,001 to 20,000 • 25%
5,000 to 10,000 • 25%
Official announcement from ICMR or Panacea Biotec
More than 90% • 25%
Less than 50% • 25%
50% to 70% • 25%
71% to 90% • 25%
Official announcement from ICMR or Panacea Biotec
Only Haryana • 25%
Multiple states in Northern India • 25%
Multiple states across India • 25%
International regions included • 25%
Official announcement from ICMR or Panacea Biotec